Latest Supply Chain News

Sigma Healthcare reports a robust 41% rise in EBIT following its merger with Chemist Warehouse, upgrading synergy targets and expanding its retail footprint internationally.

Sigma Healthcare has completed a reverse acquisition merger with Chemist Warehouse, reporting $6 billion in revenue and declaring a fully franked dividend. The merger reshapes Australia’s pharmacy landscape with ambitious synergy targets and operational shifts.

ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.

MyEco Group reported a 9% increase in FY25 sales driven by an 82% jump in MyEco branded products, alongside a strategic operational restructure aimed at cutting costs and boosting supply chain flexibility.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Ironbark Capital Limited reported a 17.6% increase in net profit for FY2025, driven by higher investment income and realised gains, alongside a raised fully franked dividend and an extended share buy-back program.

Star Combo Pharma Limited reported a 7% increase in total revenue to $27.8 million for FY25, propelled by a 10% rise in its core OEM and Own Brands segment. The company’s profit before tax surged to $5.31 million, reflecting operational strength despite challenges in its Retail division.

Chrysos Corporation reported a robust FY25 with 46% revenue growth and an 80% jump in EBITDA, driven by expanding adoption of its PhotonAssay technology and a landmark contract with gold giant Newmont. The company projects further growth in FY26 with revenue guidance of $80-90 million.

IperionX secures a $12.5 million funding tranche from the U.S. Department of Defense to fast-track expansion of its Virginia titanium manufacturing capacity beyond 1,000 metric tons annually.

Big River Industries reported a 2.3% revenue decline for FY25 amid tough market conditions but achieved a notable rebound in the second half, driven by operational efficiencies and cost controls. The company maintains a strong balance sheet and a cautiously optimistic outlook for FY26.

Big River Industries reported a modest revenue decline in FY25 but achieved improved margins and operational efficiencies in the second half, positioning itself for growth as market conditions begin to stabilise.

Big River Industries reported a statutory net loss of $14.7 million for FY2025, driven by a $20 million impairment charge on intangible assets amid a 2.3% revenue decline. Despite the setback, the company declared a fully franked 2 cent dividend and showed signs of operational stabilization.